JP2012524103A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524103A5
JP2012524103A5 JP2012506209A JP2012506209A JP2012524103A5 JP 2012524103 A5 JP2012524103 A5 JP 2012524103A5 JP 2012506209 A JP2012506209 A JP 2012506209A JP 2012506209 A JP2012506209 A JP 2012506209A JP 2012524103 A5 JP2012524103 A5 JP 2012524103A5
Authority
JP
Japan
Prior art keywords
phenyl
azabicyclo
oxa
alkyl
oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012506209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524103A (ja
JP5649643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031191 external-priority patent/WO2010120998A1/en
Publication of JP2012524103A publication Critical patent/JP2012524103A/ja
Publication of JP2012524103A5 publication Critical patent/JP2012524103A5/ja
Application granted granted Critical
Publication of JP5649643B2 publication Critical patent/JP5649643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012506209A 2009-04-17 2010-04-15 ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成 Expired - Fee Related JP5649643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17013809P 2009-04-17 2009-04-17
US61/170,138 2009-04-17
PCT/US2010/031191 WO2010120998A1 (en) 2009-04-17 2010-04-15 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses

Publications (3)

Publication Number Publication Date
JP2012524103A JP2012524103A (ja) 2012-10-11
JP2012524103A5 true JP2012524103A5 (https=) 2013-04-04
JP5649643B2 JP5649643B2 (ja) 2015-01-07

Family

ID=42269326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506209A Expired - Fee Related JP5649643B2 (ja) 2009-04-17 2010-04-15 ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成

Country Status (6)

Country Link
US (1) US8835429B2 (https=)
EP (1) EP2419432B9 (https=)
JP (1) JP5649643B2 (https=)
CA (1) CA2755554C (https=)
ES (1) ES2439793T3 (https=)
WO (1) WO2010120998A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
EP2683243A4 (en) * 2011-03-09 2014-12-03 Celgene Avilomics Res Inc PI3 KINASE INHIBITORS AND USES THEREOF
JP2014510122A (ja) * 2011-04-04 2014-04-24 セルゾーム リミテッド ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
ES2609606T3 (es) 2011-09-21 2017-04-21 Cellzome Limited Derivados de urea y carbamato de 2-morfolino-1,3,5-triazina como inhibidores de mTOR para el tratamiento de enfermedades inmunológicas o proliferativas
BR112014008241A2 (pt) 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
CN104302294A (zh) * 2011-11-01 2015-01-21 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3-激酶抑制剂的n-(3-{[(3-{[2-氯-5-(甲氧基)苯基]氨基}喹喔啉-2-基)氨基]磺酰基}苯基)-2-甲基丙氨酰胺
CN104230952B (zh) * 2014-08-16 2017-02-01 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途
AU2015366357B2 (en) * 2014-12-17 2018-07-19 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9009A (en) * 1852-06-08 Bat-trap
JP2006526652A (ja) * 2003-06-03 2006-11-24 ベス・イスラエル・ディーコニス・メディカル・センター 血管狭窄を治療するための方法及び化合物
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
MX2009002046A (es) * 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
CA2688776A1 (en) * 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2012524103A5 (https=)
ES2728163T3 (es) Compuestos de triazina como inhibidores de PI3 cinasa y mTOR
JP2011500702A5 (https=)
RS62289B1 (sr) Difluorometil-aminopiridini i difluorometil-aminopirimidini
US10022381B2 (en) Triazine compounds as PI3 kinase and mTOR inhibitors
JP5649643B2 (ja) ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
PE20061067A1 (es) Derivados de pirimidina
HK1203199B (en) Triazine compounds as pi3 kinase and mtor inhibitors
HK1157328B (en) Triazine compounds as pi3 kinase and mtor inhibitors